健友股份：关于子公司获得美国FDA来法莫林注射液药品生产场地转移注册批件的公告

Core Viewpoint - The announcement indicates that the company has received FDA approval for the production site transfer of Lamotrigine Injection, allowing its subsidiary to manufacture the product in a new facility [1] Group 1: Company Developments - The company, Jianyou Co., has announced that its subsidiary, Hong Kong Jianyou Industrial Co., has received a production site transfer approval from the U.S. FDA for Lamotrigine Injection, 150mg/15mL [1] - The approval is associated with New Drug Application (NDA) number 211673, which is crucial for the company's operational capabilities in the U.S. market [1] Group 2: Regulatory Milestones - The FDA's approval signifies a regulatory milestone for the company, enhancing its ability to produce and supply Lamotrigine Injection in compliance with U.S. standards [1] - This development may lead to increased production capacity and potential revenue growth for the company as it expands its manufacturing capabilities [1]